ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 06, 2024 16:30 ET
|
ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that...
Cognitive Testing in Clinical Drug Trials Training Course: Focus on Successful Test Selection and Integration
September 06, 2024 06:39 ET
|
Research and Markets
Dublin, Sept. 06, 2024 (GLOBE NEWSWIRE) -- The "Cognitive Testing in Clinical Drug Trials: Successful Test Selection and Integration Training Course" conference has been added to ...
Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses
September 05, 2024 08:30 ET
|
Indaptus Therapeutics
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative...
MUSIC BROKERS: 25 Years of Success and Expansion in the Music Industry
September 05, 2024 04:57 ET
|
Music Brokers
MILAN, Sept. 05, 2024 (GLOBE NEWSWIRE) -- MUSIC BROKERS celebrates its 25th anniversary, marking a significant milestone in the global music industry. Since its founding in Buenos Aires in 1997 by...
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
September 03, 2024 16:01 ET
|
Athira Pharma, Inc.
LIFT-AD trial did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23) In pre-specified subgroups of patients with moderate Alzheimer’s...
Kronos Bio Announces Participation in Medical and Investor Conferences in September
September 03, 2024 08:55 ET
|
Kronos Bio, Inc.
SAN MATEO, Calif., and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and...
Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024 08:00 ET
|
Indaptus Therapeutics
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the...
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions
August 28, 2024 09:00 ET
|
AC Immune SA
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions PI-2620 is in Phase 3 development in Alzheimer’s disease by AC Immune’s...
Habit Burger Celebrates Menu Variety with New Name: Habit Burger & Grill
August 28, 2024 07:20 ET
|
The Habit Burger Grill
IRVINE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Habit Burger, known for its award-winning Charburgers, with its iconic Double Char recently being ranked #1 in USA TODAY’s 10Best, today announces a...
Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
August 28, 2024 06:30 ET
|
Ocugen
MALVERN, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...